Every Form 4 that Avalo Therapeutics, Inc. (AVTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics, Inc. director Rita Jain received a grant of 1,322 stock options on September 30, 2026. The options were 100% vested and were issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. The report lists a transaction price of $12.29 per share and an exercise price of $15.33 per share. The options expire September 30, 2036, and Jain's reported position after the transaction was 1,322 options.
Avalo Therapeutics, Inc. director Kevin Robert Lind received 1,352 stock options on September 30, 2026. The award was 100% vested and was issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. Lind's reported post-transaction option position was 1,352.
Avalo Therapeutics, Inc. (AVTX) director Ron M. Philip received 1,109 stock options on September 30, 2026. The options were 100% vested, carry a $15.33 exercise price, and expire September 30, 2036. They were granted under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.
Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 12,394 shares of common stock on September 16, 2026 at an exercise price of $9.88 per share and sold the same number of shares at a weighted-average price of $16.33 per share. The transactions were carried out under a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, Sullivan held 83,848 options to purchase additional shares of Avalo Therapeutics common stock.
Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 10,185 shares of common stock at an exercise price of $8.04 per share on September 10, 2026, then sold 10,185 shares of common stock at a weighted average price of $17.6197 per share in multiple transactions. These trades were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, he continued to hold 105,815 options to purchase common stock at $8.04 per share, expiring on January 28, 2035, with the option vesting 25% on January 28, 2026 and the balance in equal monthly installments over the following three years, subject to continued service.
Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share. After the option exercise, Doyle held 113,734 stock options directly. All transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025, and the underlying option grant vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years.
Avalo Therapeutics, Inc. (AVTX) reported that its Chief Financial Officer, Christopher Ryan Sullivan, exercised stock options and sold common shares in mid-August 2026. He exercised options to acquire a total of 71,852 shares of common stock at an exercise price of $9.88 per share on August 17 and 18, 2026. Over the same two days, he sold 72,725 shares of common stock in open-market transactions at per-share prices reported around $19.85–$20.05, with specific trades occurring within disclosed ranges. The options exercised were part of grants expiring in 2034 and vesting 25% on March 28, 2025 and monthly thereafter. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026.
Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle. On August 17, 2026, Doyle exercised options to acquire 1,000 shares of common stock at $12.65 per share and sold 1,000 shares at $20.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle directly owned 123,750 shares of common stock.
Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a sale of 2,655 shares of common stock on August 11, 2026. The shares were sold at a weighted average price of $19.5903 per share, in multiple transactions priced between $19.54 and $19.65. Following this sale, Riley directly holds 37,041 shares of Avalo Therapeutics common stock.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle reported an option exercise and same-day share sale. On August 10, 2026, Doyle exercised a stock option for 679 shares of common stock at $8.04 per share, then sold 679 shares of common stock at $20.00 per share in a separate transaction. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle had 114,413 stock options remaining under this award.
Avalo Therapeutics Chief Medical Officer Mittie Doyle exercised 1,000 stock options on July 27, 2026 at an exercise price of $12.65 per share, receiving 1,000 shares of common stock, then sold 1,000 shares at $20.00 per share the same day. After the exercise, Doyle holds 124,750 stock options at $12.65 expiring July 15, 2034. All transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025.
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On June 30, 2026, Doyle sold 4,654 shares in an open-market sale at $20.00 per share, while also exercising options to acquire a total of 4,654 shares of common stock at strike prices of $8.04 and $12.65 per share. The options exercised relate to grants that vest over four years, and all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the trades were pre‑scheduled rather than discretionary market timing.
Avalo Therapeutics director Philip Ron M reported a grant of stock options covering 69 shares of common stock. The options were awarded on June 30, 2026 as a compensation grant, with an exercise price of $18.48 per share, are 100% vested, and expire on June 30, 2036.
Avalo Therapeutics director Kevin Robert Lind received a new stock option grant. On June 30, 2026, he was awarded options covering 1,105 shares of Avalo common stock at an exercise price of $18.48 per share. The options are 100% vested at grant and expire on June 30, 2036, leaving him with 1,105 options outstanding after this transaction.
Avalo Therapeutics director Rita Jain received a stock option grant as part of her compensation. On June 30, 2026, she was awarded options covering 1,080 shares of Avalo Therapeutics common stock at an exercise price of $18.48 per share. These options are fully vested and expire on June 30, 2036. Following this grant, she directly holds options on 1,080 underlying shares.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an exercise-and-sell transaction in company stock. On June 23, 2026, Mittie exercised options to acquire 1,450 shares of Common Stock at $8.04 per share and sold 1,450 shares at $18.00 per share in an open-market sale. Following these transactions, Mittie directly holds 51,776 Common shares and 116,871 stock options. The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were pre-scheduled rather than timed discretionarily.
Avalo Therapeutics director Philip Ron received a grant of stock options covering 40,200 shares of common stock at an exercise price of $17.83 per share. The options vest in three substantially equal annual installments on the first, second and third anniversaries of the June 23, 2026 grant date, contingent on continued board service. Following this award, his reported option holdings from this filing total 40,200 derivative securities.
Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a small administrative share disposition related to tax withholding. On June 10, 2026, 588 shares of Common Stock were withheld at $13.10 per share to cover tax obligations, rather than sold on the open market.
After this transaction, Riley directly holds 39,696 shares of Avalo Therapeutics common stock. This balance includes 3,429 shares acquired through the company’s Employee Stock Purchase Plan as part of the same reporting event, highlighting that the filing reflects routine compensation and tax mechanics.
Avalo Therapeutics Chief Legal Officer Paul Varki reported a tax-related share disposition. On this Form 4, 1,081 shares of common stock were withheld at $13.10 per share to satisfy tax obligations, a non-market transaction classified as a tax-withholding disposition.
Following this event, Varki directly holds 32,576 shares of Avalo Therapeutics common stock. A footnote explains that this total includes 5,723 shares acquired through the company’s Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported a routine tax-related share disposition. On the reported date, 138 shares of common stock were withheld at $13.10 per share to satisfy tax obligations tied to equity compensation, rather than sold in the open market. A footnote explains that this event includes 588 shares acquired through the company’s Employee Stock Purchase Plan as part of the same reporting transaction. Following these movements, Sullivan directly holds 40,773 shares of Avalo Therapeutics common stock.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle reported a small tax-related share disposition. On this Form 4, 1,084 shares of Common Stock were withheld at $13.10 per share to cover tax obligations, rather than sold on the open market. After this transaction, Doyle directly holds 51,776 shares of Avalo Therapeutics Common Stock, which includes 5,738 shares acquired through the company’s Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics director Kevin Robert Lind received a stock option grant covering 20,100 shares of Common Stock. The option has an exercise price of $13.96 per share and expires on June 2, 2036. It vests 100% on the first anniversary of the grant date, subject to his continued board service. Following this award, he holds 20,100 derivative securities directly.
Avalo Therapeutics director Samantha Truex received a new stock option grant, not an open-market share purchase. She was granted options to buy 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, contingent on her continued board service, and expire on June 2, 2036. Following this award, she holds 20,100 stock options directly, with no sales or exercises reported in this filing.
Avalo Therapeutics, Inc. director Gilla Kaplan received a grant of stock options linked to the company’s common stock. The award covers 20,100 options with an exercise price of $13.96 per share and expires on June 2, 2036.
According to the terms, the option vests 100% on the first anniversary of the grant date, as long as the director continues to serve through that date. After this grant, Kaplan holds 20,100 stock options directly, giving equity-based, long-term incentive aligned with future company performance.
Avalo Therapeutics director Aaron Kantoff received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, as long as he continues serving as a director on that date, and expire on June 2, 2036. After this grant, his total reported stock option holdings from this award are 20,100 options, with no open-market buying or selling involved.
Avalo Therapeutics, Inc. director Michael Thomas Heffernan received a grant of stock options as compensation. He was awarded 29,500 stock options, each giving the right to buy common stock at an exercise price of $13.96 per share. The options vest 100% on the first anniversary of the grant date, provided he continues to serve as a director on that vesting date. After this grant, he holds 29,500 stock options directly, and the options are scheduled to expire on June 2, 2036.
Avalo Therapeutics director Rita Jain received a new stock option grant. The award covers 20,100 options to buy Avalo Therapeutics common stock at an exercise price of $13.96 per share, with all options vesting 100% on the first anniversary of the grant date, subject to her continued board service.
Following this compensation-related grant, Jain holds 20,100 stock options directly, and the options are scheduled to expire on June 2, 2036. The filing does not show any open‑market purchases or sales of Avalo Therapeutics shares, only this option award.
Avalo Therapeutics, Inc.’s Chief Medical Officer, Doyle Mittie, reported an exercise-and-sell stock transaction. On May 28, 2026, she exercised stock options to acquire 679 shares of common stock at $8.04 per share and sold 679 shares in an open-market trade at $16.00 per share.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. Following these trades, she directly holds 47,122 shares of common stock and 118,321 stock options that remain outstanding.
Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported an acquisition of 34,200 shares of Common Stock on May 21, 2026, at a stated price of $0.00 per share. After this award, she directly holds 36,855 shares.
According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit is a contingent right to one share, tied to performance goals that the Compensation Committee certified on May 21, 2026. The shares are scheduled to fully vest on August 19, 2028, assuming her continued service.
Avalo Therapeutics, Inc. disclosed that its Chief Financial Officer, Christopher Ryan Sullivan, acquired 39,900 shares of Common Stock on May 21, 2026 in a grant/award transaction with a stated price of $0.0000 per share. Following this award, he directly holds 40,323 shares of Common Stock.
According to the accompanying disclosure, these shares relate to performance stock units (PSUs) originally granted on August 19, 2025, each representing a contingent right to receive one share of Common Stock upon achievement of specified performance goals. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares subject to the PSUs are scheduled to fully vest on August 19, 2028, subject to Sullivan’s continued service through that vesting date.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki acquired 24,300 shares of Common Stock through a compensation award. These shares relate to performance stock units granted earlier, each representing a right to one share upon meeting performance goals.
The Compensation Committee certified achievement of the required goals on May 21, 2026. As a result, the shares will fully vest on August 19, 2028, if Varki continues in service through that date. Following this award, he holds 27,934 shares directly.
Avalo Therapeutics, Inc. reported that its Chief Medical Officer, Mittie Doyle, acquired 43,500 shares of Common Stock through a compensation-related award. The transaction was coded as a grant or award, with a price per share of $0.0000, indicating no cash purchase.
Following this award, Doyle directly holds 47,122 shares of Avalo Therapeutics common stock. The award relates to performance stock units granted on August 19, 2025, which will fully vest on August 19, 2028 if specified performance goals remain achieved and Doyle continues in service through that vesting date.
Avalo Therapeutics’ CEO Neil Garry Arthur received a large equity award tied to performance. He was granted 100,200 shares of Common Stock as a grant/award acquisition at a price of $0.00 per share, increasing his direct holdings to 190,314 shares.
According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit converts into one share only if specific performance goals are met. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares are scheduled to fully vest on August 19, 2028, if he remains in service.
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On May 15, 2026, she exercised stock options to acquire 3,000 shares of common stock at $12.65 per share, then sold 3,000 shares in an open-market transaction at $18.76 per share.
After these transactions, she directly holds 3,622 shares of common stock and 128,625 stock options. The filing states the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported an option exercise and related share sale. On May 7, 2026, he exercised stock options to acquire 18,606 shares of common stock at $9.88 per share and then sold 18,606 shares in an open-market transaction at an average price of $24.1222 per share.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025, with sale prices ranging from $24.05 to $24.23. Following these transactions, he directly holds 423 shares of common stock and 168,094 stock options with a $9.88 exercise price expiring on August 13, 2034.
Avalo Therapeutics Chief Legal Officer Paul Varki reported a mix of option exercises and share sales in Avalo Therapeutics, Inc. common stock. On May 6, 2026, he exercised stock options to acquire a total of 75,063 shares of common stock at exercise prices of $8.04 and $13.43 per share.
On the same date, he sold 75,063 shares of common stock in open-market transactions at prices ranging from $18.50 to $22.88 per share. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance as part of a trading program.
Avalo Therapeutics, Inc.'s Chief Financial Officer, Christopher Ryan Sullivan, reported a combination of stock sales and option exercises. On May 6, 2026, he executed open-market sales totaling 47,000 shares of Avalo Therapeutics common stock in multiple tranches under a Rule 10b5-1 trading plan adopted on November 12, 2025, at prices ranging from $17.95 to $22.88 per share.
On the same date, he exercised stock options to acquire 47,000 common shares at an exercise price of $8.04 per share. Following these transactions, he directly holds 47,423 shares of common stock and 116,000 stock options that are scheduled to vest over time and expire on January 28, 2035.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises and related share sales in Avalo Therapeutics, Inc. common stock. On May 5–6, 2026, she exercised stock options covering 108,234 shares at strike prices of $8.04 and $12.65 per share and sold 108,234 shares in open-market transactions.
The sales occurred at prices ranging from $16.00 to about $22.88, executed in multiple trades. According to a footnote, all transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Avalo Therapeutics, Inc. director Mitchell Chan executed an open-market sale of 3,167 shares of Common Stock at $22.88 per share. The transaction occurred on May 6, 2026 and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, Chan directly holds 3,166 shares of Avalo Therapeutics common stock.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan sold 16,915 shares of common stock in open-market transactions. He sold 8,458 shares on April 29, 2026 at an average price of $13.0925 and 8,457 shares on April 30, 2026 at an average price of $13.2261. The sales were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025, with actual prices ranging from $12.61 to $13.54. Following these transactions, he directly holds 423 shares, down from 17,338 shares before the sales.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, Doyle exercised options to acquire 3,970 shares of common stock at $12.65 per share, then sold all 3,970 shares in open-market trades at an average price of about $18.01, with individual trades ranging from $18.00 to $18.10. Following the sale, Doyle directly held 3,622 shares of common stock and 210,530 stock options. The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, and that the underlying option vests over four years, with 25% vesting on July 15, 2025 and the remainder in equal monthly installments over the next three years.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported open-market sales of Avalo common stock in early April 2026. He sold a total of 15,959 shares over two days at prices around $15.858 to $17.5674 per share, in multiple transactions.
The filing notes these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025. Following the transactions, Sullivan directly holds 17,338 shares of Avalo Therapeutics common stock.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an option exercise and same-day share sale in Avalo Therapeutics, Inc. common stock. Mittie exercised stock options to acquire 679 shares of common stock at $8.04 per share, then sold 679 shares at $16.00 per share in an open-market transaction.
After these transactions, Mittie directly holds 3,622 shares of common stock and 148,329 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the timing was set in advance rather than decided on the trade date.
Avalo Therapeutics director Rita Jain received a new stock option grant. On March 31, 2026, she was granted options to acquire 1,339 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The options were granted fully vested and expire on March 31, 2036. Following this grant, she holds 1,339 options directly as reported in this filing.
Avalo Therapeutics director Kevin Robert Lind received a grant of stock options as part of his compensation. On March 31, 2026, he was awarded options to purchase 1,370 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The filing notes these options were granted on March 31, 2026 and are 100% vested, meaning they are fully exercisable immediately. After this grant, Lind holds options covering 1,370 shares, which expire on March 31, 2036 if not exercised.
Avalo Therapeutics director Samantha Truex exercised restricted stock units into common shares. On March 28, the vesting and exercise of 3,166 restricted stock units at $0.00 per unit delivered 3,166 shares of common stock, bringing her direct common stock holdings to 6,333 shares.
These units are part of a grant of 9,500 restricted stock units awarded on August 13, 2024, which vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on her continued service.
Avalo Therapeutics director Aaron Kantoff exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a stated price of $0.00 per share.
After the transaction, Kantoff directly held 6,333 shares of common stock. The restricted stock units were part of a 9,500-unit grant awarded on August 13, 2024, scheduled to vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service. No open-market buy or sell was reported in this filing; it reflects a derivative exercise tied to equity compensation.
Avalo Therapeutics director Gilla Kaplan exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a price of $0.00 per share, reflecting a routine compensation-related equity conversion rather than an open-market trade.
Following the transaction, Kaplan directly held 6,333 shares of Avalo Therapeutics common stock and 3,167 restricted stock units. The restricted stock units convert into common stock on a one-for-one basis and were part of a 9,500-unit grant made on August 13, 2024, vesting in three equal annual installments.
Avalo Therapeutics, Inc. Chief Executive Officer Neil Garry Arthur exercised restricted stock units that converted into common stock and had shares withheld for taxes. He exercised 64,866 restricted stock units into 64,866 shares of common stock at a conversion price of $0.00 per share. To satisfy tax obligations, 21,892 shares of common stock were disposed of at $13.89 per share through tax withholding, rather than an open-market sale. Following these transactions, he directly owns 90,114 shares of common stock. The restricted stock units stem from a 194,600-unit grant made on August 13, 2024, vesting in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.
Avalo Therapeutics, Inc. Chief Financial Officer Christopher Ryan Sullivan reported routine equity compensation activity involving restricted stock units (RSUs). On March 28, 2026, 24,200 RSUs converted on a one-for-one basis into 24,200 shares of common stock at a stated price of $0.00 per share.
Of the resulting common shares, 8,241 were disposed of at $13.89 per share to satisfy tax obligations, leaving 33,297 shares of common stock held directly after the transactions. A prior grant of 72,600 RSUs from August 13, 2024 vests in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.